{
    "clinical_study": {
        "@rank": "82247", 
        "arm_group": [
            {
                "arm_group_label": "Exenatide", 
                "arm_group_type": "Experimental", 
                "description": "Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections."
            }
        ], 
        "brief_summary": {
            "textblock": "We plan to examine the gastrointestinal (GI) physiologic profile of Exenatide, a\n      glucagon-like peptide (GLP-1) analog as a possible intestino-trophic growth factor capable\n      of inducing small bowel adaptation and regeneration in patients with short bowel syndrome\n      (SBS), with the potential to decrease parenteral nutrition dependence."
        }, 
        "brief_title": "Exenatide on GI Motor Function and Permeability in Short Bowel Syndrome", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Short Bowel Syndrome", 
        "condition_browse": {
            "mesh_term": "Short Bowel Syndrome"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Patients with short bowel syndrome, between the ages of 18-85 who are dependent on\n        parenteral nutrition for at least a year and are being closely followed by the Mayo Clinic\n        Home Parenteral Nutrition Program (HPN) with at least one multisystem evaluation a year."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01818648", 
            "org_study_id": "12-008505"
        }, 
        "intervention": [
            {
                "arm_group_label": "Exenatide", 
                "description": "Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.", 
                "intervention_name": "Exenatide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glucagon-Like Peptide 1", 
                "Exenatide"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 10, 2014", 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Acute Effects of a Glucagon-like Peptide 1 Analog, Exenatide, on Gastrointestinal Motor Function and Permeability in Patients With Short Bowel Syndrome on Home Parenteral Nutrition", 
        "other_outcome": [
            {
                "description": "To measure stool weight in patients with short bowel syndrome before and after administration of Exenatide compared to placebo.", 
                "measure": "Change in 24hr Stool Weight before and after administration of Exenatide vs placebo", 
                "safety_issue": "No", 
                "time_frame": "In both arms participants will collect stool weight for 24 hours in 2 seperate occasions with a wash out period of 48 hours in between collections."
            }, 
            {
                "description": "To measure urine volume in patients with short bowel syndrome before and after administration of Exenatide compared to placebo.", 
                "measure": "Change in 24hr Urine Volume before and after administration of Exenatide vs placebo", 
                "safety_issue": "No", 
                "time_frame": "In both arms participants will collect urine volume for 24 hours in 2 seperate occasions with a wash out period of 48 hours in between collections."
            }
        ], 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Michael Camilleri, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "To measure gastric, small intestinal and colonic (if applicable)  transit in patients with short bowel syndrome (SBS) before and after the administration of Exenatide compared to placebo", 
            "measure": "Change in 24hr Gastrointestinal and Colonic Transit before and after Exenatide vs placebo", 
            "safety_issue": "No", 
            "time_frame": "In both arms participants will undergo GI transit measurements on 2 seperate occasions for a total of 24 hours, with a wash out period of 48 hours in between transit studies."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01818648"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "Michael Camilleri", 
            "investigator_title": "Primary Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "To measure intestinal permeability to mannitol and lactulose in patients with short bowel syndrome before and after administration of Exenatide compared to placebo", 
            "measure": "Change in 24hr Intestinal Permeability before and after administration of Exenatide vs placebo", 
            "safety_issue": "No", 
            "time_frame": "In both arms participants will undergo intestinal permeability measurements on 2 seperate occasions for 24 hours,with a wash out period of 48 hours in between permeability studies.  ."
        }, 
        "source": "Mayo Clinic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014", 
        "why_stopped": "Study was withdrawn by PI due to decision to study a different medication."
    }
}